Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04364737 · ClinicalTrials.gov registry record · Phase 2
CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients
A Phase 2 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 941
- Enrollment target
NCT04364737: Completed Phase 2 study, sponsored by NYU Langone Health.
NCT04364737 is a Phase 2 study that has completed, run by NYU Langone Health. The registered enrollment target is 941 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (608% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04364737, a Phase 2 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 941 participants
- Enrollment target
Study Summary
This is a randomized, blinded phase 2 trial that will assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma in hospitalized patients with acute respiratory symptoms requiring oxygen supplementation.
Primary Outcome
Uninfected 0 Uninfected; no viral RNA detected Ambulatory 1 Asymptomatic; viral RNA detected 2 Symptomatic; Independent 3 Symptomatic; assistance needed Hospitalized: Mild disease 4 Hospitalized; no oxygen therapy 5 Hospitalized; oxygen by mask or nasal prongs Hospitalized: Severe disease 6 Hospitalized; oxygen by NIV or High flow 7 Intubation \& Mechanical ventilation; pO2/FIO2 \>/= 150 or SpO2/FIO2 \>/=200 8 Mechanical ventilation pO2/FIO2 \< 150 (SpO2/FIO2 \<200) or vasopressors 9 Mechani
Interventions
- BIOLOGICAL Convalescent Plasma
- OTHER Saline solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 941 participants |
| Start Date | 2020-04-17 |
| Est. Completion | 2022-12-12 |
| Phase | Phase 2 |
What the finished NCT04364737 record still lists
NCT04364737 is an interventional study that assigns participants to a tested intervention. The registered 941 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (608% higher).
The record links to 0 conditions, and to 2 interventions - of which Convalescent Plasma is the first listed.
NCT04364737 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04364737 about?
NCT04364737 is a clinical study titled "CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients". This is a randomized, blinded phase 2 trial that will assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma in hospitalized patients with acute respiratory symptoms requiring oxygen supplementation.
What is the current status of trial NCT04364737?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 941 participants. The study started on 2020-04-17. Estimated completion is 2022-12-12.
What interventions are being tested in trial NCT04364737?
The interventions under investigation include: Convalescent Plasma (BIOLOGICAL), Saline solution (OTHER).
Who is sponsoring clinical trial NCT04364737?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04364737's enrollment target sits among peer trials
941 29th of 2000 higher than 1,972 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06808334 · 942 participants
CLAiR Pivotal Study
- NCT07190209 · 942 participants · Phase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
- NCT07190222 · 942 participants · Phase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
- NCT03075696 · 940 participants · Phase 1
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI